[{"id":"6c76a251-4026-4ad4-94d6-b2b81e644662","acronym":"","url":"https://clinicaltrials.gov/study/NCT04809766","created_at":"2021-03-22T11:52:20.228Z","updated_at":"2024-07-02T16:35:24.105Z","phase":"Phase 1","brief_title":"Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT04809766","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-A • MSLN","pipe":" | ","alterations":" MSLN expression • HLA-A*02","tags":["HLA-A • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV • FH-TCR-Tᴍsʟɴ • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 12/14/2021","start_date":" 12/14/2021","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-01-09"}]